icone plus
Contact
Abonnez-vous aux actualités
Reason for request
Renewal of inclusion
Clinical Benefit
Substantial
The actual benefit of DOTAREM remains substantial.
Clinical Added Value
minor
DOTAREM offers a minor improvement in actual benefit (level IV) in terms of safety over gadolinium-based contrast media presenting a high (OMNISCAN, MAGNEVIST) or moderate (MULTIHANCE) risk of nephrogenic systemic fibrosis according to the European Medicines Agency classification.
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
5GpxW0qs7Fk7pbnb